Biopharma Bankers: Private Equity Activity Specialty Pharma???
To all Biopharma bankers out there, can someone explain why PE firms have been very active in the spec pharma/generics space over the last 5 years or so. Covis (Cerberus and now Apollo), TerSera (GTCR), Advanz (Nordic), Arbor (KKR).
In addition, anyone has a good resource to understand the spec pharma business model in-depth? How are these companies different from typical branded pharma?
Thanks folks!
Hi Analyst5432, the silence is deafening, sorry about that.... Any of the threads below helpful?
More suggestions...
I hope those threads give you a bit more insight.
BUMP
bumping ... @privateequityfolks??
It’s not high science and there are relatively predictable cash flows along with potential for operational efficiencies / rollups. Biopharma OTOH has significant binary risk dependent on clinical trial outcomes, where good data can literally add billions to a market cap overnight, and bad data vice versa.
Voluptas deleniti rem facere soluta consequatur voluptatem omnis. Nihil quam enim libero qui. Dolor neque dignissimos officia earum ipsam voluptas autem. Modi reprehenderit qui officiis esse. Quis repellat atque aspernatur voluptate consectetur eos odio est. Quia qui quibusdam aut consequatur fugit aperiam. Ullam et ratione ut minus non et qui.
Omnis rerum ut et dolor ducimus fuga nostrum. Et est consequatur architecto unde tenetur eligendi omnis. Sapiente in quia qui dolor ipsa tempore excepturi.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...